Clinically significant drug interaction: letermovir and voriconazole

Arianne Duong; Ania Sweet; Rupali Jain; Joshua A Hill; Steven A Pergam; Michael Boeckh; Catherine Liu

doi:10.1093/jac/dkz499

Clinically significant drug interaction: letermovir and voriconazole

J Antimicrob Chemother. 2020 Mar 1;75(3):775-777. doi: 10.1093/jac/dkz499.

Authors

Arianne Duong^{1

2}, Ania Sweet^{2

3}, Rupali Jain^{1

3

4}, Joshua A Hill^{2

3

4

5}, Steven A Pergam^{2

3

4

5}, Michael Boeckh^{2

3

4

5}, Catherine Liu^{2

3

4

5}

Affiliations

¹ School of Pharmacy, University of Washington, Seattle, WA, USA.
² Seattle Cancer Care Alliance, Seattle, WA, USA.
³ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁴ Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
⁵ Clinical and Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Acetates*
Drug Interactions
Pharmaceutical Preparations*
Quinazolines
Voriconazole

Substances

Acetates
Pharmaceutical Preparations
Quinazolines
letermovir
Voriconazole

Grants and funding

P30 CA015704/CA/NCI NIH HHS/United States